ACCD

6.86

104.78% 3.51

Pre-mercato: 6.83 -0.03 -0.44%

Accolade Inc (ACCD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ACCD Giù? Forum Previsione

Precedente Chiudi:

$3.35

Aprire:

$6.88

Volume 24 ore:

24.71M

Relative Volume:

15.00

Capitalizzazione di mercato:

$552.48M

Reddito:

$414.29M

Utile/perdita netta:

$-99.81M

Rapporto P/E:

-5.1393

EPS:

-1.3348

Flusso di cassa netto:

$-28.65M

1 W Prestazione:

+100.58%

1M Prestazione:

+89.50%

6M Prestazione:

+101.76%

1 anno Prestazione:

-54.24%

Intervallo 1D:

$6.84

$6.92

Intervallo di 1 settimana:

$3.33

$6.92

Portata 52W:

$3.08

$15.36

Accolade Inc Stock (ACCD) Company Profile

Nome

Accolade Inc

Settore

Healthcare (1233)

Industria

Health Information Services (1)

Telefono

610-834-2989

Indirizzo

660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING

Dipendente

2,400

Cinguettio

Prossima data di guadagno

2025-01-09

Ultimi documenti SEC

ACCD's Discussions on Twitter

Confronta ACCD con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ACCD Accolade Inc	6.86	552.48M	414.29M	-99.81M	-28.65M	-1.3348
VEEV Veeva Systems Inc	217.30	35.28B	2.66B	665.91M	1.08B	4.05
SOLV Solventum Corp	68.96	11.91B	8.26B	66.00M	1.17B	0.3682
DOCS Doximity Inc	55.00	10.27B	516.85M	174.11M	217.38M	0.87
HQY Healthequity Inc	99.74	8.64B	1.15B	96.70M	-161.99M	1.09
WAY Waystar Holding Corp	37.51	6.45B	906.14M	-52.62M	89.62M	-0.3621

Accolade Inc Stock (ACCD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-06-28	Reiterato	Needham	Buy
2024-02-26	Iniziato	Leerink Partners	Outperform
2024-01-17	Ripresa	DA Davidson	Neutral
2024-01-03	Iniziato	Barclays	Equal Weight
2023-05-24	Aggiornamento	BofA Securities	Neutral → Buy
2023-04-12	Iniziato	Stephens	Overweight
2023-03-23	Aggiornamento	Guggenheim	Neutral → Buy
2023-02-09	Downgrade	Jefferies	Buy → Hold
2023-02-02	Iniziato	Raymond James	Outperform
2022-09-08	Ripresa	Piper Sandler	Overweight
2022-09-07	Iniziato	Truist	Buy
2022-08-12	Iniziato	DA Davidson	Buy
2022-05-02	Aggiornamento	Wells Fargo	Underweight → Equal Weight
2022-04-29	Downgrade	BTIG Research	Buy → Neutral
2022-04-29	Downgrade	BofA Securities	Buy → Neutral
2022-04-29	Downgrade	Credit Suisse	Outperform → Neutral
2022-04-29	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-04-29	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-04-11	Iniziato	Wells Fargo	Underweight
2022-04-07	Iniziato	Guggenheim	Neutral
2022-04-01	Ripresa	Credit Suisse	Outperform
2022-02-11	Iniziato	Goldman	Buy
2021-12-02	Iniziato	Jefferies	Buy
2021-09-30	Iniziato	Berenberg	Buy
2021-09-17	Aggiornamento	Robert W. Baird	Neutral → Outperform
2021-05-28	Iniziato	Robert W. Baird	Neutral
2021-05-06	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2021-04-15	Iniziato	Needham	Buy
2021-03-11	Ripresa	Goldman	Buy
2021-01-15	Aggiornamento	Credit Suisse	Neutral → Outperform
2021-01-07	Iniziato	BTIG Research	Buy
2020-12-08	Iniziato	Canaccord Genuity	Buy
2020-09-22	Iniziato	DA Davidson	Buy
2020-07-27	Iniziato	BofA Securities	Buy
2020-07-27	Iniziato	Credit Suisse	Neutral
2020-07-27	Iniziato	Goldman	Buy
2020-07-27	Iniziato	Morgan Stanley	Overweight
2020-07-27	Iniziato	Piper Sandler	Overweight
2020-07-27	Iniziato	Robert W. Baird	Outperform
2020-07-27	Iniziato	SVB Leerink	Outperform

Mostra tutto

Accolade Inc Borsa (ACCD) Ultime notizie

Jan 09, 2025

Stifel Nicolaus Reaffirms Hold Rating for Accolade (NASDAQ:ACCD) - MarketBeat

Jan 09, 2025

Transcarent to acquire health advocacy and primary care company Accolade for $621m - Yahoo Finance

Jan 09, 2025

Estimate suggests Accolade may outperform with a potential 320% upside - Dataconomy

Jan 09, 2025

Accolade, with 500 employees in Montco, to be acquired in $621M deal - The Business Journals

Jan 09, 2025

Accolade (NASDAQ:ACCD) Receives Market Perform Rating from Raymond James - MarketBeat

Jan 09, 2025

Accolade to be acquired by Transcarent for $7.03 per share in cash - Yahoo Finance

Jan 09, 2025

How Accolade stock pulled off a 105% jump - Dataconomy

Jan 09, 2025

Stifel downgrades Accolade stock as competing bids deemed unlikely - Investing.com

Jan 09, 2025

Stifel Downgrades Accolade Inc. (ACCD) to Hold - StreetInsider.com

Jan 09, 2025

Raymond James Downgrades Accolade Inc. (ACCD) to Market Perform - StreetInsider.com

Jan 09, 2025

Earnings Scheduled For January 9, 2025 - Benzinga

Jan 09, 2025

Jan 08, 2025

Accolade Gets a Do-Over With Transcarent’s $621M Acquisition - MedCity News

Jan 08, 2025

Seattle health care company to go private in $621 million acquisition deal - The Business Journals

Jan 08, 2025

ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc.ACCD - Business Wire

Jan 08, 2025

Truist maintains Buy on Accolade stock, reiterates $7.50 target By Investing.com - Investing.com South Africa

Jan 08, 2025

Accolade's (ACCD) "Hold" Rating Reiterated at Needham & Company LLC - MarketBeat

Jan 08, 2025

What Transcarent's $621M Acquisition of Accolade Means for Behavioral Health - Behavioral Health Business

Jan 08, 2025

Why Is Accolade Stock Trading Over 100% On Tuesday? - Benzinga

Jan 08, 2025

What's Going On With Accolade Stock Wednesday? - Benzinga

Jan 08, 2025

Truist maintains Buy on Accolade stock, reiterates $7.50 target - Investing.com India

Jan 08, 2025

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Me - GuruFocus.com

Jan 08, 2025

Accolade (NASDAQ:ACCD) Receives Market Perform Rating from Leerink Partners - MarketBeat

Jan 08, 2025

Wilson Sonsini, Cooley Lead $621M Take-Private Of Accolade - Law360

Jan 08, 2025

Geode Capital Management Increases Stake in Accolade, Inc. – Market - HPBL

Jan 08, 2025